Nutri5® and Brain Health related to treatment of menopausal symptoms

22.10.2009 - Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller....

Earlier this year, the BBC reported that "HRT - Hormone Replacement
Therapy - can shrink women's brains"1, after a study was published
which showed that brain volume in women taking HRT was smaller in two
key areas involved in thinking and memory.

This comes in addition to earlier results from the Women's Health
Initiative (WHI) Memory Study2 that linked HRT to an increased risk
of memory loss and dementia, and an article in the Lancet3 which
concluded that HRT "substantially increases the risk of dementia of
any cause and cognitive*  decline" (* memory, thinking and
understanding).

This adds to the growing body of evidence that the risks of HRT far
outweigh any perceived benefits, evidence that Nutri Pharma feels
needs to be brought to the attention of the 150,000 women in Norway
and millions of women across Europe who are still being prescribed
this treatment.

Nutri5® is Nutri Pharma's natural product for the relief of
menopausal symptoms, shown to be effective in an open pilot study. In
addition to reducing menopausal symptoms, improving heart health and
reducing the risk of osteoporosis, clinical trials4 on soy diets
containing high levels of soy isoflavones like those found in Nutri5®
have also shown that, unlike HRT, these can actually improve the
cognitive function of post-menopausal women (aged 45+).

Dr. Bernt Rognlien of Balderklinikken, responsible for the pilot
study on Nutri5 in Norway says "these new findings confirm that the
different effects of the two treatments on brain health can be
considerable and provide yet another reason for adopting a more
natural approach to the treatment of menopausal symptoms."

Nutri Pharma has noted both the adverse effects of HRT and the
potentially positive effects of Nutri5® on cognition and is
considering whether a clinical trial can be designed to directly
compare the two approaches to the treatment of menopausal symptoms.

1.      http://news.bbc.co.uk/1/hi/health/7825116.stm  and
Resnick et al. Neurology (2009) 72:135-142
2.      Schumaker et al. JAMA. 2003 May 28;289(20):2651-62.
3.      Craig et al. Lancet Neurol. 2005 Mar.4(3):190-4.
4.      Duffy et al. Pharmacology, Biochemistry and Behaviour 75
(2003) 721-729

 

FOR FURTHER INFORMATION:

Trond Syvertsen    , CEO  +47 23 01 09 60 / + 47 91 72 14 57 

Lars Helmer Enger, CFO    +47 23 01 09 60 / + 47 90 84 37 71        

 

For information about Nutri Pharma and Nutri5®, see;
http://www.nutripharma.com and

www.nutri5.com
Oslo, 22 October 2009

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.